SSA
ITOS

Schonfeld Strategic Advisors’s iTeos Therapeutics ITOS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-57,877
Closed -$346K – 2274
2025
Q1 		$346K Sell
57,877
-5,100
-8% -$37.4K ﹤0.01% 1732
2024
Q4 		$484K Sell
62,977
-5,266
-8% -$45.2K ﹤0.01% 1424
2024
Q3 		$697K Buy
+68,243
New +$1.04M ﹤0.01% 1290
2022
Q3 		– Sell
-51,430
Closed -$1.06M – 3071
2022
Q2 		$1.06M Buy
51,430
+24,542
+91% +$582K 0.01% 1000
2022
Q1 		$865K Buy
+26,888
New +$977K 0.01% 1066

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schonfeld Strategic Advisors's ITOS Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 57,877 shares — an estimated $346K sold.

Schonfeld Strategic Advisors first reported a position in ITOS in Q1 2022 and held it in 5 quarters. The position peaked at $1.06M in Q2 2022. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 57,877 iTeos Therapeutics shares in Q2 2025, an estimated $346K.
  • Schonfeld Strategic Advisors first reported a position in iTeos Therapeutics in Q1 2022 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's iTeos Therapeutics position peaked at $1.06M in Q2 2022.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.